ANTERO-4: VIPUN Gastric Monitoring System in an Erythromycin Model

Gastric Motility Clinical Trial

— ANTERO-4  

Official title:

ANTERO-4: A Clinical Investigation of the Effects of Erythromycin on Gastric Motility, Assessed With the VIPUN Gastric Monitoring System in Healthy Adults

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04066231
• Other study ID #: S62862
• Status: Terminated
• Phase: N/A
• Start date: September 7, 2019
• Est. completion date: March 10, 2020

Study information

• Verified date: August 2020
• Source: Universitaire Ziekenhuizen Leuven
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It has been demonstrated that the VIPUN Gastric Monitoring System (GMS) can discriminate healthy physiological and pharmacologically-inhibited gastric motility, using a codeine-model in healthy adults (S60320 / AFMPS80M0687).

Erythromycin is a gastroprokinetic agent, known to stimulate gastric contractility. A single dose of 200 mg erythromycin has been shown to induce a prolonged period of enhanced phasic contractile activity.

The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.

The performance of the VIPUN GMS can be enhanced by data-driven optimization of the VIPUN Motility Algorithm, used to quantify gastric motility.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: March 10, 2020
• Est. primary completion date: March 10, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Signed Informed Consent

• Aged between and including 18 and 65 years

• BMI between and including 18 and 30

• Understand and able to read Dutch

• In good health on the basis of medical history

• Refrains from herbal, vitamin and other dietary supplements on the day of the visits

Exclusion Criteria:

• Dyspeptic symptoms (assessed with PAGI-SYM questionnaire)

• Using any medication that might affect gastric function or visceral sensitivity

• Known / suspected current use of illicit drugs

• Known psychiatric or neurological illness

• Any gastrointestinal surgery that could influence normal gastric function in the opinion of the investigator

• History of heart or vascular diseases like irregular heartbeats, angina or heart attack

• Nasopharyngeal surgery in the last 30 days

• Suspected basal skull fracture or severe maxillofacial trauma

• History of thermal or chemical injury to upper respiratory tract or esophagus

• Current esophageal or nasopharyngeal obstruction

• Known coagulopathy

• Known esophageal varices

• Pregnant or breastfeeding women

• Have known side-effects/allergic reactions when taking erythromycin or other macrolide antibiotics (such as azithromycin, clarithromycin)

• Kidney disease

• Liver disease

• Myasthenia gravis

• QT prolongation (QT =400 ms) at the screening

• Cardiac arrhythmia or heart failure

• History of C. difficile infection

• Family history of QT prolongation, sudden cardiac death or other heart problems

• Recent vaccinations with live bacterial vaccines (such as typhoid vaccine)

• Concomitant medication use

Related Conditions & MeSH terms

• Gastric Motility

Intervention

Device:
• VIPUN GMS
Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).

Drug:
• Erythromycin Lactobionate
Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults. Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium.

Locations

Country	Name	City	State
Belgium	UZ Leuven	Leuven

Sponsors (1)

Lead Sponsor	Collaborator
Prof Dr Jan Tack

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	GBMI baseline	Gastric Balloon Motility Index (GBMI) is measured with the VIPUN Gastric Monitoring System. GBMI is a value between 0 and 1.	t = 0 - 119 minutes
Primary	GBMI120 - 139	Motility during erythromycin administration. Gastric Balloon Motility Index (GBMI) is measured with the VIPUN Gastric Monitoring System. GBMI is a value between 0 and 1.	t = 120 - 139 minutes
Secondary	GBMI140-240	Motility in the period 140 - 240 minutes. Gastric Balloon Motility Index (GBMI) is measured with the VIPUN Gastric Monitoring System. GBMI is a value between 0 and 1.	t = 140 - 240 minutes
Secondary	Symptoms	Epigastric symptoms (nausea, bloating, pain) are surveyed with Visual Analogue Scales for severity of each individual symptom (100 mm, 0 = Absent to 100 mm = worst possible sensation) at a 15 minute interval.	t = 0 - 240 minutes
Secondary	Incidence of adverse events	Incidence of adverse events	t = 0 - 240 minutes
Secondary	Severity of adverse (device) events/effects	Severity of adverse (device) events/effects	t = 0 - 240 minutes
Secondary	Seriousness of adverse (device) events/effects	Seriousness of adverse (device) events/effects	t = 0 - 240 minutes
Secondary	Relatedness of adverse (device) events/effects	Relatedness of adverse (device) events/effects	t = 0 - 240 minutes
Secondary	Incidence of device deficiencies of the investigational medical device	Qualitative description of the event, onset, duration, origin, action taken and outcome of the event	t = 0 - 240 minutes
Secondary	Incidence of protocol deviations related to the investigational medical device	Qualitative description of the event, onset, duration, origin, action taken and outcome of the event	t = 0 - 240 minutes